Dexmedetomidine for the prevention of delirium in critically ill patients: A protocol for a systematic review

Mathias Maagaard*, Marija Barbateskovic, Anders Perner, Janus Christian Jakobsen, Jørn Wetterslev

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Resumé

Background: Delirium is a common complication in critically ill patients and carries an increased risk of mortality and morbidity. Dexmedetomidine can potentially prevent delirium by diminishing predisposing factors. The evidence regarding the use of dexmedetomidine in preventing delirium is conflicting. This protocol aims to identify the beneficial and harmful effects of dexmedetomidine in the prevention of delirium. Methods: This protocol uses the recommendations of the Cochrane Collaboration, the Preferred Report Items of Systematic Reviews with Meta-Analysis Protocols, and the eight-step assessment procedure suggested by Jakobsen and colleagues. We wish to assess in critically ill patients, if dexmedetomidine versus placebo can reduce the incidence of delirium and improve clinical outcomes. We will include all randomised trials assessing the use of dexmedetomidine in the prevention of delirium. To identify trials, we will search the Cochrane Central Register of Controlled Trials, Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Latin American and Caribbean Health Sciences Literature, Science Citation Index Expanded on Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Chinese Science Journal Database, and BIOSIS. Two authors will screen the literature and extract data. We will use the Cochrane risk of bias tool to evaluate trials. Extracted data will be analysed using Review Manager 5 and Trial Sequential Analysis. We will create a “Summary of Findings”-table in which we will present our primary and secondary outcomes. We will assess the quality of evidence using GRADE. Discussion: This systematic review can potentially aid clinicians in decision-making and benefit the many critically ill patients at risk of delirium.

OriginalsprogEngelsk
TidsskriftActa Anaesthesiologica Scandinavica
Vol/bind63
Udgave nummer4
Sider (fra-til)540-548
Antal sider9
ISSN0001-5172
DOI
StatusUdgivet - 1. apr. 2019

Fingeraftryk

Dexmedetomidine
Critical Illness
Databases
MEDLARS
Causality
Meta-Analysis
China
Placebos
Incidence
Health

Citer dette

Maagaard, Mathias ; Barbateskovic, Marija ; Perner, Anders ; Jakobsen, Janus Christian ; Wetterslev, Jørn. / Dexmedetomidine for the prevention of delirium in critically ill patients : A protocol for a systematic review. I: Acta Anaesthesiologica Scandinavica. 2019 ; Bind 63, Nr. 4. s. 540-548.
@article{89a4ee7aad8f43c0b7c05fe6ca903cbc,
title = "Dexmedetomidine for the prevention of delirium in critically ill patients: A protocol for a systematic review",
abstract = "Background: Delirium is a common complication in critically ill patients and carries an increased risk of mortality and morbidity. Dexmedetomidine can potentially prevent delirium by diminishing predisposing factors. The evidence regarding the use of dexmedetomidine in preventing delirium is conflicting. This protocol aims to identify the beneficial and harmful effects of dexmedetomidine in the prevention of delirium. Methods: This protocol uses the recommendations of the Cochrane Collaboration, the Preferred Report Items of Systematic Reviews with Meta-Analysis Protocols, and the eight-step assessment procedure suggested by Jakobsen and colleagues. We wish to assess in critically ill patients, if dexmedetomidine versus placebo can reduce the incidence of delirium and improve clinical outcomes. We will include all randomised trials assessing the use of dexmedetomidine in the prevention of delirium. To identify trials, we will search the Cochrane Central Register of Controlled Trials, Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Latin American and Caribbean Health Sciences Literature, Science Citation Index Expanded on Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Chinese Science Journal Database, and BIOSIS. Two authors will screen the literature and extract data. We will use the Cochrane risk of bias tool to evaluate trials. Extracted data will be analysed using Review Manager 5 and Trial Sequential Analysis. We will create a “Summary of Findings”-table in which we will present our primary and secondary outcomes. We will assess the quality of evidence using GRADE. Discussion: This systematic review can potentially aid clinicians in decision-making and benefit the many critically ill patients at risk of delirium.",
keywords = "Delirium, dexmedetomidine, meta-analysis, systematic review, Systematic review registration: CRD42018115560, trial sequential analysis",
author = "Mathias Maagaard and Marija Barbateskovic and Anders Perner and Jakobsen, {Janus Christian} and J{\o}rn Wetterslev",
year = "2019",
month = "4",
day = "1",
doi = "10.1111/aas.13313",
language = "English",
volume = "63",
pages = "540--548",
journal = "Acta Anaesthesiologica Scandinavica",
issn = "0001-5172",
publisher = "Wiley-Blackwell",
number = "4",

}

Dexmedetomidine for the prevention of delirium in critically ill patients : A protocol for a systematic review. / Maagaard, Mathias; Barbateskovic, Marija; Perner, Anders; Jakobsen, Janus Christian; Wetterslev, Jørn.

I: Acta Anaesthesiologica Scandinavica, Bind 63, Nr. 4, 01.04.2019, s. 540-548.

Publikation: Bidrag til tidsskriftReviewForskningpeer review

TY - JOUR

T1 - Dexmedetomidine for the prevention of delirium in critically ill patients

T2 - A protocol for a systematic review

AU - Maagaard, Mathias

AU - Barbateskovic, Marija

AU - Perner, Anders

AU - Jakobsen, Janus Christian

AU - Wetterslev, Jørn

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: Delirium is a common complication in critically ill patients and carries an increased risk of mortality and morbidity. Dexmedetomidine can potentially prevent delirium by diminishing predisposing factors. The evidence regarding the use of dexmedetomidine in preventing delirium is conflicting. This protocol aims to identify the beneficial and harmful effects of dexmedetomidine in the prevention of delirium. Methods: This protocol uses the recommendations of the Cochrane Collaboration, the Preferred Report Items of Systematic Reviews with Meta-Analysis Protocols, and the eight-step assessment procedure suggested by Jakobsen and colleagues. We wish to assess in critically ill patients, if dexmedetomidine versus placebo can reduce the incidence of delirium and improve clinical outcomes. We will include all randomised trials assessing the use of dexmedetomidine in the prevention of delirium. To identify trials, we will search the Cochrane Central Register of Controlled Trials, Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Latin American and Caribbean Health Sciences Literature, Science Citation Index Expanded on Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Chinese Science Journal Database, and BIOSIS. Two authors will screen the literature and extract data. We will use the Cochrane risk of bias tool to evaluate trials. Extracted data will be analysed using Review Manager 5 and Trial Sequential Analysis. We will create a “Summary of Findings”-table in which we will present our primary and secondary outcomes. We will assess the quality of evidence using GRADE. Discussion: This systematic review can potentially aid clinicians in decision-making and benefit the many critically ill patients at risk of delirium.

AB - Background: Delirium is a common complication in critically ill patients and carries an increased risk of mortality and morbidity. Dexmedetomidine can potentially prevent delirium by diminishing predisposing factors. The evidence regarding the use of dexmedetomidine in preventing delirium is conflicting. This protocol aims to identify the beneficial and harmful effects of dexmedetomidine in the prevention of delirium. Methods: This protocol uses the recommendations of the Cochrane Collaboration, the Preferred Report Items of Systematic Reviews with Meta-Analysis Protocols, and the eight-step assessment procedure suggested by Jakobsen and colleagues. We wish to assess in critically ill patients, if dexmedetomidine versus placebo can reduce the incidence of delirium and improve clinical outcomes. We will include all randomised trials assessing the use of dexmedetomidine in the prevention of delirium. To identify trials, we will search the Cochrane Central Register of Controlled Trials, Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Latin American and Caribbean Health Sciences Literature, Science Citation Index Expanded on Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Chinese Science Journal Database, and BIOSIS. Two authors will screen the literature and extract data. We will use the Cochrane risk of bias tool to evaluate trials. Extracted data will be analysed using Review Manager 5 and Trial Sequential Analysis. We will create a “Summary of Findings”-table in which we will present our primary and secondary outcomes. We will assess the quality of evidence using GRADE. Discussion: This systematic review can potentially aid clinicians in decision-making and benefit the many critically ill patients at risk of delirium.

KW - Delirium

KW - dexmedetomidine

KW - meta-analysis

KW - systematic review

KW - Systematic review registration: CRD42018115560

KW - trial sequential analysis

U2 - 10.1111/aas.13313

DO - 10.1111/aas.13313

M3 - Review

C2 - 30671925

AN - SCOPUS:85060532216

VL - 63

SP - 540

EP - 548

JO - Acta Anaesthesiologica Scandinavica

JF - Acta Anaesthesiologica Scandinavica

SN - 0001-5172

IS - 4

ER -